Omeros Co. (NASDAQ:OMER - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 earnings estimates for Omeros in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst O. Brayer anticipates that the biopharmaceutical company will earn ($1.14) per share for the year. The consensus estimate for Omeros' current full-year earnings is ($3.09) per share.
Omeros (NASDAQ:OMER - Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.05).
A number of other equities research analysts also recently commented on OMER. Wall Street Zen downgraded Omeros from a "hold" rating to a "sell" rating in a report on Friday, June 6th. Needham & Company LLC reissued a "hold" rating on shares of Omeros in a research note on Friday, May 16th. D. Boral Capital reissued a "buy" rating and set a $36.00 price target on shares of Omeros in a research report on Tuesday, May 13th. Finally, HC Wainwright initiated coverage on Omeros in a research report on Tuesday. They issued a "buy" rating and a $9.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $18.00.
Check Out Our Latest Analysis on Omeros
Omeros Price Performance
Shares of Omeros stock traded down $0.15 on Tuesday, hitting $3.40. 696,461 shares of the company's stock traded hands, compared to its average volume of 688,448. The firm's 50-day moving average price is $5.11 and its two-hundred day moving average price is $7.74. The stock has a market capitalization of $199.22 million, a PE ratio of -1.47 and a beta of 2.20. Omeros has a one year low of $2.97 and a one year high of $13.60.
Institutional Trading of Omeros
Several hedge funds and other institutional investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Omeros by 3.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,831 shares of the biopharmaceutical company's stock worth $314,000 after buying an additional 1,110 shares during the period. Truvestments Capital LLC lifted its stake in Omeros by 116.5% in the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company's stock valued at $31,000 after acquiring an additional 1,669 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in Omeros by 79.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company's stock worth $44,000 after acquiring an additional 1,972 shares during the last quarter. Deutsche Bank AG grew its stake in shares of Omeros by 4.9% during the 1st quarter. Deutsche Bank AG now owns 42,019 shares of the biopharmaceutical company's stock worth $345,000 after acquiring an additional 1,973 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its stake in shares of Omeros by 2.0% during the 4th quarter. Ameriprise Financial Inc. now owns 120,493 shares of the biopharmaceutical company's stock worth $1,190,000 after acquiring an additional 2,317 shares in the last quarter. Institutional investors and hedge funds own 48.79% of the company's stock.
About Omeros
(
Get Free Report)
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.
Recommended Stories
Before you consider Omeros, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omeros wasn't on the list.
While Omeros currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
